Yüklüyor......
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance
SIMPLE SUMMARY: Nowadays, many patients with chronic lymphocytic leukemia (CLL) are treated with so-called novel agents, including BTK inhibitors, Bcl-2 inhibitors and PI3K inhibitors. As CLL is a chronic disease, most patients will relapse on or after treatment with these drugs and various mechanis...
Kaydedildi:
| Yayımlandı: | Cancers (Basel) |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8002361/ https://ncbi.nlm.nih.gov/pubmed/33809580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061336 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|